Plain-language summary available for the TORREY seralutinib study

PHA Canada
Mar 17, 2025
1 min read

Seralutinib is a molecule that blocks inflammation, cell proliferation, and scarring responsible for pulmonary arterial hypertension. The Phase 2 TORREY study looked at whether inhaled seralutinib may be an effective and safe treatment for pulmonary arterial hypertension.

After 24 weeks, participants in the TORREY study who took seralutinib lowered the resistance to blood flow through the lungs by 14% more than those who took the placebo.

Research is continuing because of the positive TORREY study results, with the phase 3 PROSERA study now underway.

Read a plain-language summary of the TORREY study results

Recent Posts

Exercise is safe and effective for PH patients

Researchers conducted a meta-analysis, looking at 13 studies with about 700 participants in total with pulmonary hypertension (PH). They found that exercise improved 6-minute walk distance and was con

In CTEPH, antioxidant enzyme PRDX2 reduces inflammation

A study found that chronic thromboembolic pulmonary hypertensio (CTEPH) patients had significantly more of an antioxidant enzyme (peroxiredoxin 2, or PRDX2) in their bloodstream compared to healthy pa

Early diagnosis and treatment of PAH improve survival

This study examined the causes of delayed diagnosis (diagnosis after approximately 22 months) of pulmonary arterial hypertension (PAH) and whether an earlier diagnosis (within six months) leads to bet